ArticleJournal of asthma and allergy2021
Erratum: Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum].
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
ArticleJournal of asthma and allergy2021
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.